Navigation Links
Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
Date:4/5/2011

SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, reported interim results from Phase 1 dose-escalation clinical trials demonstrating that administration of JX-594 targets tumor vasculature. By directly targeting and replicating within tumor vasculature, JX-594 disrupts the blood supply to the solid tumors contributing to destruction of the cancer. Data were reported in a poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

"In addition to targeting, infecting and destroying cancer cells and stimulating a targeted immune response against remaining cancer cells, the analysis presented at AACR demonstrates JX-594's critical third mechanism of action—the disruption of the blood supply to the tumor," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  

"Importantly, these data show that both intravenous and intratumoral injection of JX-594 can effectively attack tumor vasculature. These results further demonstrate that JX-594 may have therapeutic benefit for a variety of solid tumors including liver, colorectal and other cancers," added Philippe Archinard, chairman and chief executive officer of Transgene.

Twenty three patients were enrolled in the Phase 1 dose-escalation clinical study using intravenous JX-594 to treat advanced, treatment refractory solid tumors. Tumor biopsies, evaluated through immunohistochemical analysis, showed that JX-594 given intravenously infected the vasculature of tumors causing the blood supply to the tumor to be disrupted. In addition, in another trial of patients with primary liver can
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
2. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
5. Jennerex Appoints Lara Longpre to Chief Operating Officer
6. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
7. Jennerex Announces Presentations at Upcoming Conferences
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
(Date:5/4/2015)... of the cuvette manufacturing world, opened their doors to the public in early 2015.  ... offering scientists amazing support for their spectroscopy needs.  ... ... ... In mid-2014 Simcha Woitovich ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3
(Date:5/4/2015)... 04, 2015 Malibu Biotech Systems ... breath spray. KissSafe™ is the first personal hygiene ... experience while adding fresh breath appeal. KissSafe™ contains ... kills germs in the mouth and oral cavity ... ingredients that possess additional wellness benefits. KissSafe’s proprietary ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... The opportunity for children to dream of a bright ... behind The Fairy Godmother Next Door, a new children’s picture ... , The inspiration for the enchanting story of a fairy ... desire to be a fairy godmother. , “My wish came ... neighbors’ children since they were born. We discuss fairies and ...
(Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... behaviors, study says , , THURSDAY, Nov. 6 (HealthDay News) ... much lower in areas that have lots of green ... large British study finds. , Dr. Richard Mitchell, of ... previous studies have shown that the presence of green ...
... Calif., Nov. 6 Lumenis(R) Ltd. a global,developer, ... for ophthalmic, surgical and aesthetic applications,announced today that ... devices on November 8th at the American Academy ... Dov Ofer, Lumenis, President and Chief Executive Officer ...
... of veterans with posttraumatic stress disorder (PTSD) raises the ... and children in communities across the United States," says ... and an assistant professor of social work at Washington ... are very different than those for PTSD. The Department ...
... Texas, Nov. 6 The following was released ... A recent report from the U.S. Department of ... 08-01105-171) substantiated waste,mismanagement and inaction to disclosures of ... Central Texas Veterans Health,Care System (CTVHCS)., Inaction ...
... 6 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... Officer of Savient Pharmaceuticals,will present a corporate update ... The presentation is scheduled to begin on November ... The Conference will be held at the Arizona,Biltmore ...
... 6 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... anti-infective products, today,announced that three patents protecting Moxatag ... Orange Book on,Oct. 24, 2008, pursuant to Section ... on Oct. 8, 2008., MiddleBrook President & ...
Cached Medicine News:Health News:Green Areas Lower Health Inequities Between Rich, Poor 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 3Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 4Health News:Growing problem for veterans: Domestic violence 2Health News:War Veterans With Traumatic Brain Injury Pay the Price of Waste at the VA, Says Dr. Robert Van Boven 2Health News:Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 3Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: